ACCORD: Bursaries for patient and public involvement in research
MHRA suspends use of certain Gadolinium contrast agents (GdCAs), and restricts uses of others.
A class 2 medicine recall – action within 48 hours – has now been issued by the MHRA for Magnevist (Bayer plc) and Omniscan Solution (GE Healthcare).
Changes to IRAS from 18 October 2017
Changes to IRAS - Effective June 28th 2017
The eHealth IT Security policy is available here: http://www.accord.scot/researcher-access/ehealth-it-security-policy
Statement from the MHRA on inspections of Labs analysing human samples as part of a clinical trial.
The 2016 Accord brochure can be found HERE
Management of Deviations & Violations Training Materials available.
New HRA Approval documents are available